JAMP-ASA 81MG EC TABLET (ENTERIC-COATED)

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

ACETYLSALICYLIC ACID

זמין מ:

VITA HEALTH PRODUCTS INC

קוד ATC:

B01AC06

INN (שם בינלאומי):

ACETYLSALICYLIC ACID

כמות:

81MG

טופס פרצבטיות:

TABLET (ENTERIC-COATED)

הרכב:

ACETYLSALICYLIC ACID 81MG

מסלול נתינה (של תרופות):

ORAL

יחידות באריזה:

1000

סוג מרשם:

OTC

איזור תרפויטי:

SALICYLATES

leaflet_short:

Active ingredient group (AIG) number: 0101169013; AHFS:

מצב אישור:

APPROVED

תאריך אישור:

2014-07-30

מאפייני מוצר

Jamp - ASA 81 mg EC Page 1 of 46
PRODUCT MONOGRAPH
JAMP - ASA 81 MG EC
Acetylsalicylic
Acid Delayed Release Tablets
81 mg
USP
Platelet aggregation inhibitor
Vita Health Products Inc.
150 Beghin Avenue
Winnipeg,
MB
Canada R2J 3W2
Control Number: 264031
Date of Preparation:
February 3, 2011
Date of Revision :
September 1, 2022
Jamp - ASA 81 mg EC Page 2 of 46
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
4
ADVERSE REACTIONS
........................................................................................................
7
DRUG INTERACTIONS
........................................................................................................
7
DOSAGE AND ADMINISTRATION
.....................................................................................
9
OVERDOSAGE.....................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
....................................................................11
STORAGE AND STABILITY
...............................................................................................13
DOSAGE FORMS, COMPOSITION AND
PACKAGING......................................................13
PART II: SCIENTIFIC INFORMATION
.........................................................................
14
PHARMACEUTICAL INFORMATION
................................................................................14
CLINICAL
TRIALS................................................................